Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
140.50    3.25 (2.36%)
Bid:
138.00
Ask:
144.50
Spread: 6.50 (4.71%)
Market Cap: £110.25m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Systems integration partner

13 May 2005 07:01

Xaar PLC13 May 2005 FOR IMMEDIATE RELEASE 13 May 2005 Xaar plc IMPIKA APPOINTED AS SYSTEMS INTEGRATION PARTNER Xaar plc ("Xaar"), the inkjet printing technology group headquartered inCambridge, and IMPIKA SA ("IMPIKA") of Aubagne, France are pleased to announce ajoint agreement for the provision of integration services for Xaar printheadsand other products. Under the agreement both parties will co-operate to provide complete turnkeysolutions for clients wishing to use Xaar technology for their productionprocesses, to open up new applications and create bespoke solutions. IMPIKA haslong experience with inkjet, including its application to the printing ofplastic and smart cards, packaging, labelling as well as special applicationsfor printing on CDs, glass and metal. Impika is also developing solutions basedon its material jetting technology for microelectronics and biomedicalapplications. Nigel Berry, Deputy CEO of Xaar commented: "I am very pleased to announce thisrelationship with IMPIKA. We previously stated our intention to partner with asmall number of high quality integrators which can offer existing and potentialusers of our technology a complete package of integration skills and bespokeequipment. We have known the team at IMPIKA for some time now and have beenimpressed by their standards and innovation. I look forward to working withthem on future projects." Paul Morgavi, IMPIKA'S CEO said: "Xaar is a great partner for us and we arealready forming strong links with their technical and marketing teams. There isa clear synergy between Xaar and Impika with both parties introducing newmarkets into the joint relationship. Last year we introduced our C9000 productbased on Xaar's Leopard printhead and we are working on various projects foradapting our IPS print engine to the next generation of Xaar printheads, likethe Omnidot and HSS. Full commercial release of these products is anticipatedlater this year or early next year." About Xaar Xaar plc is a market-leading inkjet technology company. It targets the world'sindustrial, commercial and office printing markets. The industrial andcommercial printing markets are targeted by Xaar's own range of inkjet productsin conjunction with partners and other key players in those markets; the officeprinting market is approached through Xaar's strong list of licensees.Additional information about Xaar is available at www.xaar.co.uk. About IMPIKA: Created in March 2003 as a spin-out from Gemplus, IMPIKA is headquartered atAubagne in the south of France. IMPIKA offers high-performance industrialprinting and material jetting solutions using inkjet technology; it currentlyhas 37 employees. IMPIKA designs, develops, implements and markets hardware and softwaresolutions, as well as the required engineering as regards ink and materialjetting, for industrial applications including digital printing,microelectronics and biotechnologies. Additional information about IMPIKA isavailable at www.impika.com. Contacts Xaar plc: 01223-423663Ian Dinwoodie, Chief Executive www.xaar.co.ukNigel Berry, Group Finance Director & Deputy Chief Executive IMPIKA: +33 (0)4 42 62 43 00Paul Morgavi, CEO www.impika.com Bankside Consultants:Steve Liebmann 020-7444-4163 /07802-888159 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20221:10 pmRNSTotal Voting Rights
21st Jun 20225:20 pmRNSDirector Declaration - Additional Directorship
1st Jun 202210:22 amRNSTotal Voting Rights
25th May 20221:57 pmRNSResult of AGM
3rd May 20225:20 pmRNSTotal Voting Rights
7th Apr 20226:31 pmRNSPDMR Shareholding
7th Apr 20222:50 pmRNSGrant of Options and Deferred Bonus Share Awards
1st Apr 202210:48 amRNSTotal Voting Rights
29th Mar 20227:00 amRNS2021 Full Year Results
28th Mar 202210:44 amRNSHolding(s) in Company
21st Mar 202212:37 pmRNSNotice of 2021 Preliminary Results
3rd Mar 20227:00 amRNSAcquisition of Megnajet
1st Mar 20225:29 pmRNSTotal Voting Rights
1st Feb 20225:00 pmRNSTotal Voting Rights
18th Jan 20224:35 pmRNSPrice Monitoring Extension
13th Jan 20227:00 amRNSTrading Update
4th Jan 20222:39 pmRNSBlock listing Interim Review
4th Jan 20222:37 pmRNSTotal Voting Rights
10th Dec 20214:23 pmRNSGrant of Awards - Replacement
6th Dec 202112:25 pmRNSHolding(s) in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
5th Nov 202110:30 amRNSGrant of Sharesave Options
1st Nov 20214:11 pmRNSCompletion of Divestment of Xaar 3D
1st Nov 20211:56 pmRNSTotal Voting Rights
29th Oct 20214:41 pmRNSSecond Price Monitoring Extn
29th Oct 20214:36 pmRNSPrice Monitoring Extension
25th Oct 202110:38 amRNSResult of General Meeting
15th Oct 202111:50 amRNSGrant of Options and Deferred Bonus Share Awards
14th Oct 20218:44 amRNSBlock Listing Application
13th Oct 20212:52 pmRNSHolding(s) in Company
6th Oct 20212:43 pmRNSPublication of Circular and Notice of GM
6th Oct 20217:00 amRNSProposed divestment of Xaar 3D
1st Oct 202111:59 amRNSTotal Voting Rights
14th Sep 20217:00 amRNS2021 Interim Results
3rd Sep 202112:59 pmRNSNotice of 2021 Interim Results
2nd Sep 20213:40 pmRNSTotal Voting Rights
2nd Aug 20215:02 pmRNSTotal Voting Rights
22nd Jul 20217:00 amRNSTrading Update
12th Jul 20217:00 amRNSAcquisition of FFEI
1st Jul 20213:20 pmRNSBlock listing Interim Review
1st Jul 202110:51 amRNSTotal Voting Rights
22nd Jun 20215:37 pmRNSHolding(s) in Company
22nd Jun 202111:44 amRNSHolding(s) in Company
16th Jun 20211:17 pmRNSResult of AGM
1st Jun 202110:10 amRNSTotal Voting Rights
17th May 20219:27 amRNSHolding(s) in Company
12th May 202110:15 amRNSHolding(s) in Company
4th May 20213:01 pmRNSTotal Voting Rights
30th Apr 20216:23 pmRNSAnnual Financial Report
27th Apr 20217:00 amRNS2020 FULL YEAR RESULTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.